Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Basal cell carcinoma, drawn from the whole corpus: 25 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
1 medicines on record are linked to one of the types below rather than to Basal cell carcinoma itself. Grouped by the type that holds them; each list opens that type's own page.
Hedgehog-inhibitor tolerability leads most patients to stop within a year.
Nothing recorded yet.
Background: Immune-related adverse events (irAEs). Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Resistance via SMO mutations has no approved next-in-class agent.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Huge volume: dermatology and Mohs capacity, and cost of treating millions of low-risk lesions.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Nobody knows how many there are. The registration rule recorded only the first basal cell carcinoma per person for two decades, the annual method that replaced it finds 67 percent more, and that method still misses about 14 tumours per 100 patients. Dermatology and Mohs capacity is commissioned against the smaller number.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Risk stratification depends on a pattern that is often mixed and not always reproducible. Most tumours are composite, there is no evidence about what proportion of a high-risk pattern is biologically significant, and the joint Royal College of Pathologists and British Association of Dermatologists audit found risk status among the most frequently omitted core items in skin cancer reports.
Superficial basal cell carcinoma has no agreed definition and may not be invasive at all. The UK dataset records that there is no consensus on whether it is in situ or invasive, no consensus on its exact definition, and that studies quote various thicknesses, all under 1 mm; that is why the dataset deliberately avoids the phrase invasive basal cell carcinoma in its own title.
The volume is the problem. Millions of low-risk lesions have to be treated to prevent the small number of destructive ones, and the whole cost of that falls on a disease that is left out of the national cancer statistics.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
The first drug ever approved for the commonest cancer in human beings is not recommended by NICE for it, and neither sonidegib nor cemiplimab in this disease has been appraised at all.
Hedgehog inhibitors are stopped by most people who start them, with a median treatment duration of 8.6 months in the largest study, and neither intermittent dosing nor topical delivery has yet produced a licensed alternative.
Acquired smoothened mutations restore hedgehog signalling downstream of the drug and there is no approved next-in-class agent; the working answer is to change pathway entirely and use a PD-1 antibody.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 35 changes by month →When this page itself was last checked or edited.
Two different questions get muddled here and they have different answers. Will this one come back: usually not, and the risk depends on what it was and how it was treated. In the Dutch randomised trial of high-risk facial basal cell carcinoma, ten-year recurrence was 4.4 percent after Mohs and 12.2 percent after standard excision for primary tumours, and 3.9 against 13.5 percent for recurrent ones; the same trial found that 56 percent of the recurrences of primary tumours appeared more than five years after treatment, which is why a clear five years is reassuring but is not the end of the story for a high-risk lesion on the face. Will I get another one: probably, and sooner than you would guess. In a meta-analysis of 17 studies, the three-year cumulative risk of a further basal cell carcinoma after a first was 44 percent, at least ten times the rate of first tumours in a comparable population, while the risk of a squamous cell carcinoma after a basal cell carcinoma was 6 percent. Those are cohort figures rather than a prediction for you, and they are about new cancers on damaged skin rather than this one returning. What follow-up is offered follows from that, and it is lighter than most people expect. The BAD says not everyone needs it, that people are usually discharged if the recurrence risk is low and they are not at high risk of future skin cancers, and that it is considered for advanced disease, a high risk of recurrence, or a high risk of multiple cancers such as people with weakened immune systems or genetic syndromes. Cancer Research UK says an early basal cell carcinoma may mean a single follow-up appointment and then none. Being discharged is not being dropped: it is a transfer of the surveillance to you, and both the BAD and Cancer Research UK are explicit about what you are then meant to do. The BAD puts a frequency on it, once a month, with someone else looking at the places you cannot see; Cancer Research UK asks you to know what your skin normally looks like and does not name an interval. Both say to go to the GP for any mark that is growing, changing, bleeding or not healing, including a change where this one was treated.
Post hoc analyses in 17 participants suggested that patidegib topical gel reduced the number of new surgically eligible basal cell carcinomas and the level of hedgehog signalling, with minimal adverse effects; no pre-specified endpoint was met.
Freedom from treatment failure at five years 77.
Advanced basal cell carcinoma after hedgehog inhibitor
For a large facial basal cell carcinoma where the operation would cost an eyelid or a nostril, a hedgehog inhibitor can be given first. VISMONEO gave vismodegib for a mean of 6.0 months to 55 patients with a mean lesion size of 47.3 mm and downstaged the planned surgery in 44 of them (80 per cent, 67 to 90), with 27 complete responses of which 25 were proved on biopsy. The part usually left out belongs in the conversation: at three years 16 of those 44 patients had a known recurrence, 36 per cent. The drug changes the operation, it does not replace it.